PL414785A1 - 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance - Google Patents
3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substanceInfo
- Publication number
- PL414785A1 PL414785A1 PL414785A PL41478515A PL414785A1 PL 414785 A1 PL414785 A1 PL 414785A1 PL 414785 A PL414785 A PL 414785A PL 41478515 A PL41478515 A PL 41478515A PL 414785 A1 PL414785 A1 PL 414785A1
- Authority
- PL
- Poland
- Prior art keywords
- dodecylsulfanyl
- butyric acid
- medicine
- active substance
- composition containing
- Prior art date
Links
- JKQDAUBTRADMCZ-UHFFFAOYSA-N 3-dodecylsulfanylbutanoic acid Chemical compound CCCCCCCCCCCCSC(C)CC(O)=O JKQDAUBTRADMCZ-UHFFFAOYSA-N 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Przedmiotem zgłoszenia jest kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do stosowania w leczeniu i profilaktyce rozwoju insulinooporności. Zgłoszenie dotyczy także kompozycji farmaceutycznej, charakteryzującej się tym, że jako substancję czynną zawiera kwas 3-dodecylosulfanylomasłowy oraz zastosowania kwasu 3-dodecylosulfanylomasłowego do wytwarzania leku do zapobiegania insulinooporności.The subject of the application is 3-dodecylsulfanylbutyric acid for use as a medicine, especially for use in the treatment and prevention of the development of insulin resistance. The application also relates to a pharmaceutical composition characterized in that it contains 3-dodecylsulfanylbutyric acid as the active substance and the use of 3-dodecylsulfanylbutyric acid in the manufacture of a medicament for the prevention of insulin resistance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL414785A PL228077B1 (en) | 2015-11-13 | 2015-11-13 | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL414785A PL228077B1 (en) | 2015-11-13 | 2015-11-13 | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL414785A1 true PL414785A1 (en) | 2017-05-22 |
| PL228077B1 PL228077B1 (en) | 2018-02-28 |
Family
ID=58709075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL414785A PL228077B1 (en) | 2015-11-13 | 2015-11-13 | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL228077B1 (en) |
-
2015
- 2015-11-13 PL PL414785A patent/PL228077B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL228077B1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018076601A2 (en) | oral pharmaceutical formulation, methods for treating a patient, and use of a formulation | |
| MX378273B (en) | ACTIVE COMPOUNDS TOWARDS BROMODOMAINS. | |
| EA201591003A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EA201401028A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY | |
| EA201692301A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| MX375752B (en) | BRUTON'S TYROSINE KINASE INHIBITORS. | |
| EA201591004A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EA201590058A1 (en) | ANALOGUE GLUACAGONA | |
| EA202090683A2 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
| CY1122899T1 (en) | AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN | |
| EA201791333A1 (en) | GLUCAGON DERIVATIVES WITH IMPROVED STABILITY | |
| EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
| EA201591698A1 (en) | MACRO CYCLIC INHIBITORS OF KINASE LRRK2 | |
| EP3597208A4 (en) | PHARMACEUTICAL COMPOSITION WITH ATPIF1 FOR THE TREATMENT OF DIABETES | |
| BR112017012406A2 (en) | fixed ratio formulation of insulin glargine / lixisenatide | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| EA201591773A1 (en) | MACRO CYCLIC INHIBITORS RIP2-KINASE | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| PL414785A1 (en) | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance | |
| TR201903234T4 (en) | Pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease. | |
| UA107884C2 (en) | Combined anti-tuberculosis drug | |
| PL399880A1 (en) | 8- (octadecylsulfanyl) quinoline for use as a medicine, especially for use in the treatment and prophylaxis of insulin resistance development, a pharmaceutical composition containing 8- (octadecylsulfanyl) quinoline and the use of 8- (octadecylsulfanyl) quinoline for the preparation of a medicament for use in the treatment and prophylaxis of insulinopathy | |
| MD20150017A2 (en) | Use of Polybiolin drug in patients with liver cirrhosis |